Birgit Bossenmaier

2.4k total citations
42 papers, 1.8k citations indexed

About

Birgit Bossenmaier is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Birgit Bossenmaier has authored 42 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 19 papers in Radiology, Nuclear Medicine and Imaging and 17 papers in Oncology. Recurrent topics in Birgit Bossenmaier's work include Monoclonal and Polyclonal Antibodies Research (18 papers), HER2/EGFR in Cancer Research (13 papers) and Metabolism, Diabetes, and Cancer (11 papers). Birgit Bossenmaier is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (18 papers), HER2/EGFR in Cancer Research (13 papers) and Metabolism, Diabetes, and Cancer (11 papers). Birgit Bossenmaier collaborates with scholars based in Germany, Switzerland and United States. Birgit Bossenmaier's co-authors include Thomas Friess, Max Hasmann, Helmut Burtscher, Josef Endl, Werner Scheuer, A. Ullrich, Monika Kellerer, Gerhard Niederfellner, Gwendlyn Kollmorgen and Hans-Ulrich Häring and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and PLoS ONE.

In The Last Decade

Birgit Bossenmaier

41 papers receiving 1.7k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Birgit Bossenmaier	816	807	659	281	180	42	1.8k
Jie Zang	593 0.7×	655 0.8×	404 0.6×	126 0.4×	477 2.6×	95	2.0k
Christina Ravera	554 0.7×	716 0.9×	223 0.3×	94 0.3×	111 0.6×	15	1.3k
Johann Zimmermann	764 0.9×	1.2k 1.5×	122 0.2×	140 0.5×	205 1.1×	41	1.9k
Lars Damstrup	910 1.1×	902 1.1×	208 0.3×	122 0.4×	452 2.5×	43	1.9k
Mika K. Derynck	553 0.7×	648 0.8×	183 0.3×	193 0.7×	308 1.7×	34	1.5k
Kathleen D. Whitney	695 0.9×	775 1.0×	82 0.1×	239 0.9×	135 0.8×	25	1.6k
Peter Shintaku	630 0.8×	1.0k 1.3×	97 0.1×	273 1.0×	190 1.1×	30	1.9k
Yasir H. Ibrahim	828 1.0×	1.1k 1.3×	163 0.2×	82 0.3×	305 1.7×	22	1.6k
Qianming Bai	314 0.4×	412 0.5×	183 0.3×	86 0.3×	171 0.9×	82	1.2k
Susana Constantino Rosa Santos	464 0.6×	664 0.8×	127 0.2×	224 0.8×	105 0.6×	41	1.3k

Countries citing papers authored by Birgit Bossenmaier

Since Specialization

Citations

This map shows the geographic impact of Birgit Bossenmaier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birgit Bossenmaier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birgit Bossenmaier more than expected).

Fields of papers citing papers by Birgit Bossenmaier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Birgit Bossenmaier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birgit Bossenmaier. The network helps show where Birgit Bossenmaier may publish in the future.

Co-authorship network of co-authors of Birgit Bossenmaier

This figure shows the co-authorship network connecting the top 25 collaborators of Birgit Bossenmaier. A scholar is included among the top collaborators of Birgit Bossenmaier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Birgit Bossenmaier. Birgit Bossenmaier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

O'Brien, James, Xiufen Liu, Tapan K. Bera, et al.. (2017). Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. Cancer Immunology Research. 5(8). 685–694. 39 indexed citations

Collins, Denis M., Wolfgang Jacob, Juan Miguel Cejalvo, et al.. (2017). Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer. PLoS ONE. 12(5). e0177331–e0177331. 39 indexed citations

Bauss, Frieder, Martin Lechmann, Ben‐Fillippo Krippendorff, et al.. (2016). Characterization of a re‐engineered, mesothelin‐targetedPseudomonasexotoxin fusion protein for lung cancer therapy. Molecular Oncology. 10(8). 1317–1329. 48 indexed citations

Meneses‐Lorente, Georgina, Thomas Friess, Gabriele Hölzlwimmer, et al.. (2015). Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody. Cancer Chemotherapy and Pharmacology. 75(4). 837–850. 13 indexed citations

Goller, Sabine, et al.. (2015). Deciphering the Stepwise Binding Mode of HRG1β to HER3 by Surface Plasmon Resonance and Interaction Map. PLoS ONE. 10(2). e0116870–e0116870. 7 indexed citations

Schmid, Volker, Dieter Heindl, Sebastian Dziadek, et al.. (2014). Development of Bispecific Molecules for the In Situ Detection of Protein-Protein Interactions and Protein Phosphorylation. Chemistry & Biology. 21(3). 357–368. 7 indexed citations

Schiller, Christian, Thomas Friess, Christian A. Gerdes, et al.. (2013). RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation. Cancer Research. 73(16). 5183–5194. 85 indexed citations

Kollmorgen, Gwendlyn, Gerhard Niederfellner, Alexander Lifke, et al.. (2013). Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy. Molecular Oncology. 7(6). 1142–1151. 26 indexed citations

Gerdes, Christian A., Valeria Nicolini, Sylvia Herter, et al.. (2012). GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab. Clinical Cancer Research. 19(5). 1126–1138. 98 indexed citations

10.

Metz, Stewart A., Alexander K. Haas, Benson Wui-Man Lau, et al.. (2012). Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Engineering Design and Selection. 25(10). 571–580. 28 indexed citations

11.

Kollmorgen, Gwendlyn, Birgit Bossenmaier, Gerhard Niederfellner, Hans‐Ulrich Häring, & Reiner Lammers. (2012). Structural Requirements for Cub Domain Containing Protein 1 (CDCP1) and Src Dependent Cell Transformation. PLoS ONE. 7(12). e53050–e53050. 11 indexed citations

12.

Scheuer, Werner, Thomas Friess, Helmut Burtscher, et al.. (2009). Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models. Cancer Research. 69(24). 9330–9336. 460 indexed citations

13.

Gerdes, Christian, Monika Patre, Valeria Nicolini, et al.. (2008). GA201, a novel humanized, glycoengineered EGFR antibody with enhanced ADCC and superior in vivo efficacy in xenograft models. Cancer Research. 68. 3973–3973. 3 indexed citations

14.

Wisniewska, M., Birgit Bossenmaier, Guy Georges, et al.. (2005). The 1.1Å Resolution Crystal Structure of the p130cas SH3 Domain and Ramifications for Ligand Selectivity. Journal of Molecular Biology. 347(5). 1005–1014. 19 indexed citations

15.

Hennige, Anita M., Jan Krützfeldt, Birgit Bossenmaier, et al.. (2000). Serine residues 994 and 1023/25 are important for insulin receptor kinase inhibition by protein kinase C isoforms β2 and θ. Diabetologia. 43(4). 443–449. 47 indexed citations

16.

Stoyanov, Borislav, et al.. (1997). Impact of Mutations at Different Serine Residues on the Tyrosine Kinase Activity of the Insulin Receptor. Biochemical and Biophysical Research Communications. 239(1). 235–239. 23 indexed citations

17.

Bossenmaier, Birgit, et al.. (1997). A 973 valine to methionine mutation of the human insulin receptor: interaction with insulin-receptor substrate-1 and Shc in HEK 293 cells. Diabetologia. 40(10). 1135–1140. 6 indexed citations

18.

Bossenmaier, Birgit, Luitgard Mosthaf, Harald Mischak, A. Ullrich, & Hans‐Ulrich Häring. (1997). Protein kinase C isoforms β 1 and β 2 inhibit the tyrosine kinase activity of the insulin receptor. Diabetologia. 40(7). 863–866. 83 indexed citations

19.

Bossenmaier, Birgit, Monika Kellerer, Edison Capp, et al.. (1996). Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling.. Journal of Clinical Investigation. 97(6). 1471–1477. 181 indexed citations

20.

Bühring, Hans‐Jörg, Ronald Herbst, Birgit Bossenmaier, et al.. (1993). Modulation of p145c-kit function in cells of patients with acute myeloblastic leukemia.. PubMed. 53(18). 4424–31. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact